Device Firm Earnings Roundup
This article was originally published in The Gray Sheet
In this earnings review, we look at recent financial reports from Atricure, Greatbatch, Medtronic, Nevro and Endologix.
You may also be interested in...
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.